Simplified procedures for the determination of fenoldopam and its metabolites in human plasma by high-performance liquid chromatography with electrochemical detection: comparison of manual and robotic sample preparation methods

Boppana, Venkata K.; Dolce, Kathleen M.; Cyronak, Matthew J.; Ziemniak, J

doi:10.1016/s0378-4347(00)83046-7

Cited by 27 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma samples were analyzed by high‐performance liquid chromatography with mass spectrometric detection based on a prior published method (Boppana et al. , 1989) with modification as follows.…”

Section: Methodsmentioning

confidence: 99%

“…Each dog received 12 mL of intravenous sterile saline at each sample time to replace lost volume. Blood tubes were immediately placed on ice and centrifuged for 10 min at 3000 g. Resultant plasma was immediately transferred to polypropylene tubes containing 0.1 mL (100 lL) of 10% (weight ⁄ volume percent) ascorbic acid solution (as recommended by Boppana et al, 1989), mixed, and stored immediately at )20°C. Samples were kept frozen prior to analysis.…”

Section: Blood Sample Collectionmentioning

confidence: 99%

“…Plasma samples were analyzed by high-performance liquid chromatography with mass spectrometric detection based on a prior published method (Boppana et al, 1989) with modification as follows. Polypropylene tubes (15 mL) containing 1 mL of plasma sample and 50 ng of SKF-38393 hydrochloride (internal standard; Sigma-Aldrich, St Louis, MO, USA) in 25 lL of 50 mM acetic acid and 0.5 mL of 0.5 M dibasic sodium phosphate were prepared.…”

Section: Determination Of Blood Fenoldopam Concentrationsmentioning

confidence: 99%

See 2 more Smart Citations

Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs

Bloom

Labato

Hazarika

et al. 2011

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Fenoldopam is a selective dopamine-1 receptor agonist that causes peripheral arterial vasodilation, increased renal blood flow, and diuresis. Enthusiasm exists for the use of fenoldopam in non-polyuric kidney injury in dogs, though pharmacokinetic data is lacking. The purpose of this study was to collect basic pharmacokinetic and hemodynamic effect data for fenoldopam when administered to healthy awake dogs. Six healthy, awake beagles were given a 180 minute fenoldopam constant rate infusion at 0.8 μg/kg/min followed by a 120 minute washout period. Citrated blood was collected during and after infusion for plasma fenoldopam concentration measurement by HPLC with mass spectrometry. Heart rate and indirect systolic blood pressure were concurrently measured. Mean +/− SD steady state plasma fenoldopam concentrations of 20 +/− 17 ng/mL were achieved within 10 min of starting the infusion. Area under the plasma concentration-time curve was 3678 +/− 3030 ng/mL*min and plasma clearance was 66 +/− 43 mL/min/kg. Elimination was rapidly achieved in all dogs. Heart rate and systolic blood pressure were unaffected by the fenoldopam infusion. Based on the results of this study, further evaluation of the effects of fenoldopam in dogs at differing doses and in dogs with clinical conditions such as acute non-polyuric kidney injury is warranted.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Blood Sample Collectionmentioning

confidence: 99%

Section: Determination Of Blood Fenoldopam Concentrationsmentioning

confidence: 99%

See 1 more Smart Citation

Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs

Bloom

Labato

Hazarika

et al. 2011

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…Plasma fenoldopam concentrations were deter mined using high-performance liquid chromatogra phy with electrochemical detection after liquid/liquid extraction of fenoldopam from the plasma samples as previously reported [4], Solutions of the drugs were prepared daily in ster ile saline.…”

Section: Analytical Proceduresmentioning

confidence: 99%

Pharmacology of SK&F R-105058 and R-106114, N-Ethyl Carbamate Ester Prodrugs of Fenoldopam

Brooks

DePalma²,

Cyronak³

et al. 1990

Pharmacology

Self Cite

View full text Add to dashboard Cite

The pharmacology of SK&F R-105058 and SK&F R-106114, N-ethyl carbamate ester prodrugs of fenoldopam, was evaluated in pentobarbital-anesthetized dogs. The selective dopamine 1 (DA1) antagonist, SCH 23390, significantly attenuated the renal vasodilator effects of SK&F R-82526, the active enantiomer of fenoldopam. This dose of SCH 23390 also significantly attenuated the increase in renal blood flow and decrease in renal vascular resistance induced by the administration of either SK&F R-106114 or SK&F R-105058. The cholinesterase inhibitor, physostigmine, at a dose that significantly enhanced the renal effects of acetylcholine, did not alter the in vivo renal vasodilator effects of SK&F R-105058 or prevent conversion of SK&F R-105058 to fenoldopam. Thus, these data indicate that the renal vasodilator activity of fenoldopam prodrugs involves activation of DA1 receptors and that, unlike other carbamate ester prodrugs, conversion to the parent compound is unlikely to involve cholinesterase.

show abstract

“…8 DA-1 stimulation produces vasodilation by inducing vascular smooth muscle relaxation. 22 The postulated mechanisms of vasodilation include a reduction in cytosolic calcium and an increase in cyclic adenine monophosphate levels. 23 Several investigators have characterized the renal effects of fenoldopam, which include a decrease in RVR and increases in renal blood flow (RBF), GFR, renal sodium, and water excretion.…”

mentioning

confidence: 99%

Dopamine‐1 Receptor Agonist: Renal Effects and Its Potential Role in the Management of Radiocontrast‐Induced Nephropathy

Asif

Epstein

2004

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Radiocontrast-induced nephropathy remains the third leading cause of hospital-acquired acute renal failure. Once established, this syndrome is associated with increased morbidity and mortality as well as increased health care costs. Recently, studies have been initiated to evaluate the potential of a selective dopamine-1 receptor agonist (fenoldopam) in ameliorating radiocontrast-induced renal failure. Selective dopamine-1 receptor agonists exhibit many desirable renal effects that support their use for the prophylaxis of radiocontrast-induced nephropathy, including decreases in renal vascular resistance and increases in renal blood flow, glomerular filtration, and sodium and water excretion. Several reports have documented a beneficial effect of fenoldopam administration in attenuating radiocontrast-induced nephropathy. In contrast, a recent multicenter, randomized study did not demonstrate a renoprotective effect of fenoldopam against radiocontrast-induced nephropathy. The presence of multiple confounders, however, precludes a definitive conclusion regarding the ability of fenoldopam to protect against radiocontrast-induced nephropathy. Additional studies are needed to properly evaluate the role of fenoldopam in radiocontrast-induced nephropathy prophylaxis.

show abstract

Simplified procedures for the determination of fenoldopam and its metabolites in human plasma by high-performance liquid chromatography with electrochemical detection: comparison of manual and robotic sample preparation methods

Cited by 27 publications

References 5 publications

Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs

Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs

Pharmacology of SK&F R-105058 and R-106114, N-Ethyl Carbamate Ester Prodrugs of Fenoldopam

Dopamine‐1 Receptor Agonist: Renal Effects and Its Potential Role in the Management of Radiocontrast‐Induced Nephropathy

Contact Info

Product

Resources

About

Simplified procedures for the determination of fenoldopam and its metabolites in human plasma by high-performance liquid chromatography with electrochemical detection: comparison of manual and robotic sample preparation methods

Cited by 27 publications

References 5 publications

Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs

Preliminary pharmacokinetics and cardiovascular effects of fenoldopam continuous rate infusion in six healthy dogs

Pharmacology of SK&amp;F R-105058 and R-106114, N-Ethyl Carbamate Ester Prodrugs of Fenoldopam

Dopamine‐1 Receptor Agonist: Renal Effects and Its Potential Role in the Management of Radiocontrast‐Induced Nephropathy

Contact Info

Product

Resources

About

Pharmacology of SK&F R-105058 and R-106114, N-Ethyl Carbamate Ester Prodrugs of Fenoldopam